Key findings

  • r=0.22 vs r=0.03breast-cancer-specific anxiety versus general anxiety after a false positive, in a meta-analysis of 17 studies and 20,781 participants; no association with general depression
  • 15.9 pointslower return to routine screening after short-interval follow-up than the 76.9% after a true-negative result (10.0 after biopsy recommendation, 1.9 after additional imaging)
  • 0.61 vs 0.44differences at 12-14 years: existential values reached p < 0.01, while the difference in anxiety did not (p = 0.11)
  • 58.0% vs 16.0%anxiety responses when an artificial-intelligence discordance was disclosed, versus the scenario without artificial intelligence; 25.3% with a contextual explanation (hypothetical scenarios, 600 women)

Abstract

A false-positive mammographic screening result can produce distress that does not resolve immediately once cancer has been ruled out. This narrative review examines its psychological and behavioral consequences and the role of communication during the diagnostic work-up.

A structured PubMed search, run on September 6, 2026, was complemented by citation tracking and review of scientific society guidelines. Systematic reviews, observational studies, qualitative research, and intervention studies were integrated, distinguishing direct evidence in women with abnormal or false-positive results from evidence drawn from other populations.

Findings are more consistent for breast-cancer-specific distress and worry than for general anxiety or depression. Some studies document consequences over several years; at 12-14 years, one cohort showed differences mainly in existential values, without a statistically significant difference in anxiety. The association with subsequent screening attendance varies across settings. Qualitative studies highlight uncertainty, clarity of explanations, and the opportunity to ask questions. Communication-based and organizational interventions show heterogeneous results: some show less fear or anxiety, while others assess comprehension, accessibility, or diagnostic timelines. Evidence on communicating artificial-intelligence results comes from a single study using hypothetical scenarios.

Communication is a modifiable component of care after an abnormal result. Explaining uncertainty, ensuring an understandable follow-up plan, and offering accessible support are evidence-consistent practices, although their effect on persistent distress and future participation requires further evaluation. The goal should include informed decision-making and women's well-being, in addition to timely clinical follow-up.

Introduction

Mammography screening can detect breast cancer before symptoms appear, but it also generates false-positive results. A false positive is an initially abnormal finding that requires further evaluation and, once the diagnostic process is complete, is not confirmed as cancer. This definition depends on the outcome of the evaluation rather than on an isolated radiological category. During the interval before resolution, the result remains abnormal or indeterminate; it cannot be communicated as an already-confirmed false positive.1,2

The frequency of false-positive results depends on age, breast density, screening interval, and program organization. In England, 2009-2010 data collected by Bond et al. showed a 3.9% recall rate; 80.5% of these women did not have cancer, equivalent to 3.1% of all women screened.1 In United States studies synthesized by Nelson et al., the cumulative risk of at least one false positive over ten years was approximately 61% with annual screening and 42% with biennial screening.2 These historical figures describe specific populations and schedules; they should not be interpreted as universal rates or confused with the risk from a single round.

The relevance of the false positive extends beyond the need for additional testing. Reviews describe breast-cancer worry, altered risk perception, and distress related to future mammograms, with less consistent findings for general anxiety and depression.3,4 The absence of a demonstrated clinical disorder does not imply an absence of suffering, but neither does it allow specific distress to be equated with psychiatric illness.

The association with subsequent screening attendance is heterogeneous and may reflect both individual experiences and health system characteristics.3,5 Communication matters on both fronts: it helps women understand the result and coordinate the evaluation, while women's accounts point to information and support needs that can persist after cancer has been ruled out.

Given this evidence, the problem cannot be addressed solely through test sensitivity and specificity; it requires understanding the psychological impact and how clinician-patient communication may modulate it. The aim of this narrative review is to synthesize the available evidence on the psychological impact of false positives in breast cancer screening, addressing their magnitude, their specificity relative to other mental-health outcomes, and their possible influence on future adherence, as well as to analyze the modulating role of clinician-patient communication in the experience and consequences of this result.

Methods

We conducted a narrative review supported by a structured PubMed search with no initial language or date restrictions, run on September 6, 2026. The search combined four conceptual blocks of title and abstract terms: (A) false positive or recall ("false positive," "false-positive," "false positives," recall, "abnormal mammogra*," "abnormal screening"); (B) mammography or breast cancer screening (mammogra*, "breast cancer screening," "breast screening"); (C) psychological outcomes (anxiety, distress, psycholog*, psychosocial, worry, "quality of life"); and (D) clinician-patient communication (communicat*, "physician-patient," "patient-physician," "doctor-patient," "patient-provider," "risk communication," "shared decision," "decision aid*," disclos*, notif*, and the MeSH term Physician-Patient Relations). The combination A AND B AND C yielded 299 records; adding block D narrowed this to 44; and applying a systematic review or meta-analysis filter to the first combination yielded 27. These sets overlap and do not represent a total of independent studies. Records were screened by title and abstract, and the full texts of potentially relevant articles were reviewed. We supplemented the search with backward and forward citation tracking of the most frequently cited reviews and cohort studies1,4,6 and with a review of ASCO guidelines on patient-clinician communication and on anxiety and depression in people with cancer.

We included systematic reviews, meta-analyses, and cohort, cross-sectional, qualitative, and intervention studies involving women who received an abnormal or false-positive result after mammographic screening and that reported psychological, behavioral, or communication-related outcomes. Studies on the communication of results, the organization of diagnostic assessment, or informed decision-making in screening were included when they provided relevant indirect evidence, and they are identified as such in the text. Studies focused exclusively on diagnostic accuracy, imaging technique, or algorithm performance, without psychological, behavioral, or communication outcomes, were excluded. Narrative selection prioritized relevance to psychological impact and to the communication of the result.

For each study, we extracted the design, population and sample size, instruments, time of assessment, and main results, with measures of effect and precision when reported. The synthesis was organized by outcome, stage of the diagnostic process, and study design. Confirmed false positives were distinguished from abnormal results still under evaluation, and direct evidence was distinguished from extrapolations drawn from general screening or oncology care. No new meta-analysis was performed, and no formal risk-of-bias or certainty-of-evidence assessment was conducted. Search counts describe the documented literature-search process and not a systematic selection reproduced for this review.

Results

Psychological and behavioral consequences of false positives

Studies use generic instruments, such as the State-Trait Anxiety Inventory (STAI), the Hospital Anxiety and Depression Scale (HADS), and the General Health Questionnaire, together with condition-specific measures, such as the Psychological Consequences Questionnaire and the Consequences of Screening in Breast Cancer (COS-BC). The latter assesses multiple dimensions related to the screening experience.6 The choice of instrument and timing of measurement shapes the results obtained. Long et al. identified 47 articles, noted heterogeneity in constructs and measures, and found no theoretical justification for their selection.7 For this reason, worry, anxiety, distress, and psychosocial change should not be treated as interchangeable outcomes.

The meta-analysis by Salz et al., with 17 studies and 20,781 participants, found larger associations for breast-cancer-specific outcomes: specific anxiety, r=0.22 (95% CI 0.18-0.27); specific distress, r=0.16 (0.10-0.22); and specific worry, r=0.12 (0.08-0.16). The effect on general anxiety was small, r=0.03 (0.00-0.07), and no association with general depression was observed, r=0.00 (-0.04 to 0.04).4 The systematic review by Brewer et al. described a similar pattern.3 In the British review by Bond et al., condition-specific measures detected consequences up to 35 months later, while generic measures showed no differences at the earlier time points examined.1,8 This supports distinguishing screening-related distress from general symptoms, without assuming that any single instrument rules out a clinical diagnosis.

Distress tends to increase during diagnostic uncertainty. Heckman et al. followed 98 women and observed an increase in state anxiety after being notified of the need for further testing, followed by a decrease after resolution.9 In Barcelona, Espasa et al. compared 150 women: worry about breast cancer was 46% after non-invasive evaluation and 52% after invasive evaluation, versus 10% with negative results, with no significant between-group differences on the HADS.10 The review by Metsälä et al. likewise highlighted prediagnostic anxiety, although findings on its duration were variable.11 Individual trajectories and differences between instruments preclude assigning a single duration to the psychological impact.

Evidence from outside European and North American settings broadens this picture but requires consideration of design differences. In a cross-sectional study from Jordan, 168 women with false positives and 504 controls showed differences on the combined anxiety/depression domain of the EQ-5D: 69% versus 32% reported problems.12 This finding does not equate to a prevalence of diagnosed anxiety or depressive disorders, nor does it allow causality to be attributed to the false positive alone. Comparison with studies using other instruments or measurement time points should be made cautiously.

The Danish cohort of Brodersen and Siersma provides longitudinal follow-up using the COS-BC. At 36 months, women with false positives scored higher than those with normal results on all 12 dimensions assessed, but only four differences reached the p<0.01 significance threshold used by the authors. The difference in anxiety was 0.87 points (95% CI 0.17-1.56; p=0.014), which did not reach that threshold. Comparisons with women who had cancer on some dimensions do not constitute evidence of equivalence between the two experiences.6

In the 12-14-year extension, 761 women responded, including 156 with false positives. Scores were higher than the normal-result group on all 14 dimensions (the questionnaire had been extended with two Part II scales, empathy and impulsivity, measured only at this follow-up), but only existential values reached p<0.01: a difference of 0.61 points (95% CI 0.15-1.06; p=0.009). The difference in anxiety was 0.44 points (-0.11 to 0.98; p=0.11). Part II of the COS-BC captures changes that can be positive or negative; therefore, existential values is not synonymous with persistent anxiety. These results suggest possible prolonged psychosocial consequences, with uncertainty arising from losses to follow-up and changes in exposures over the years elapsed.13

The role of diagnostic invasiveness remains uncertain. In an analysis of the same Danish cohort, Heleno et al compared 170 women managed without invasive procedures and 82 who underwent fine-needle aspiration or biopsy, finding no statistically significant differences across 60 comparisons.14 Confidence intervals were wide, and the authors themselves acknowledged that they could not exclude relevant differences. The Bond review reported greater distress after invasive procedures in some of the included studies.1,8 Taken together, these findings do not allow the conclusion that invasiveness is irrelevant, nor do they establish that communication has a larger effect than the procedure itself.

Regarding subsequent screening attendance, Brewer et al. found higher reattendance after false-positive results in the United States (RR 1.07; 95% CI 1.02-1.12), no clear association in Europe (RR 0.97; 0.93-1.01), and lower return in Canada (RR 0.63; 0.50-0.80).3 A European update described persistent heterogeneity.5 In the United States, a more recent Breast Cancer Surveillance Consortium cohort of more than one million women found lower return to routine screening after false-positive results: compared with 76.9% after a true-negative result, return was 1.9, 10.0, and 15.9 percentage points lower after recall for additional imaging, biopsy recommendation, and short-interval follow-up, respectively.15 That the lowest return followed short-interval surveillance rather than biopsy suggests that prolonged uncertainty, and not only invasiveness, may shape subsequent behavior. In a broader meta-analysis of attendance factors, Mottram et al. found lower attendance after a false positive (OR 0.77; 95% CI 0.68-0.88), based on six studies with 3,540,953 women; the associations were analyzed univariably.16 These estimates do not demonstrate that anxiety mediates the effect: access, invitation practices, and follow-up pathways may also play a role. Moreover, not returning to the program on record does not always equate to abandoning mammographic surveillance altogether. The Bond review included a low-quality trial of invitation letters tailored to the prior result, with a favorable signal for return (RR 1.10; 95% CI 1.00-1.21), insufficient to establish a universal strategy.1

The evidence supports a specific psychological impact in a subset of women, with variable duration and magnitude. The association with future attendance should be analyzed separately, distinguishing compliance with diagnostic evaluation after an abnormal finding from return to routine screening after a benign result. Table 1 summarizes the main studies on these consequences.

Table 1. Main studies on the psychological and behavioral consequences of false-positive results

StudyDesign and populationMeasures and follow-upMain findings
Salz et al.4Meta-analysis; 17 studies, 20,781 participants.Generic and breast-cancer-specific psychosocial outcomes.Specific anxiety r=0.22 (95% CI 0.18-0.27); general anxiety r=0.03 (0.00-0.07); no association with depression.
Brewer et al.3Systematic review; 23 studies, 313,967 women.Long-term behavior, well-being, and beliefs.Higher but not pathologically elevated distress; return to screening RR 1.07 (United States), 0.97 (Europe), and 0.63 (Canada).
Bond et al.1,8Systematic review (Health Technology Assessment).Generic and condition-specific measures.Specific consequences up to 35 months; no differences on generic measures at the earlier time points examined.
Heckman et al.9Prospective study; 98 recalled women.State anxiety at three time points.Anxiety increased after notification and decreased after resolution.
Espasa et al.10Comparative study; 150 women, Barcelona.Breast-cancer worry; HADS.Worry 46% (non-invasive) and 52% (invasive evaluation) versus 10% (negative result); no differences on HADS.
Gharaibeh et al.12Cross-sectional; 168 false positives and 504 controls, Jordan.EQ-5D.Problems in the anxiety/depression domain, 69% versus 32%.
Brodersen and Siersma6Danish cohort.COS-BC; 36 months.Higher scores on all 12 dimensions; four differences reached p<0.01.
Gram et al.13Danish cohort extension; 761 respondents, 156 with false positives.COS-BC; 12-14 years.Only existential values reached p<0.01 (0.61; 95% CI 0.15-1.06); anxiety 0.44 (p=0.11).
Heleno et al.14Danish cohort; 170 non-invasive versus 82 invasive evaluations.COS-BC.No significant differences in 60 comparisons; wide confidence intervals.
Miglioretti et al.15Breast Cancer Surveillance Consortium cohort; more than one million women.Return to routine screening.Return 1.9, 10.0, and 15.9 percentage points lower after additional imaging, biopsy, and short-interval follow-up, respectively, versus 76.9% after a true negative.
Mottram et al.16Meta-analysis; six studies, 3,540,953 women.Screening attendance.Lower attendance after a false positive, OR 0.77 (95% CI 0.68-0.88), univariable analyses.

COS-BC: Consequences of Screening in Breast Cancer; EQ-5D: EuroQol 5-dimension questionnaire; HADS: Hospital Anxiety and Depression Scale; OR: odds ratio; RR: risk ratio.

Women's qualitative experience

Qualitative studies describe how women experience a false-positive screening result, with recurring themes across countries and healthcare settings. A thematic synthesis of seven qualitative studies conducted in the United Kingdom, Sweden, Denmark, Norway, Hong Kong, and the United States identified three major narrative threads: prior expectations about one's own health, the experience of uncertainty, and, finally, the restoration of the healthy self.17 In these studies, many women attended screening expecting confirmation that they were healthy, and the recall letter was experienced as a disruption of that expectation. Some participants' self-concept shifted from "healthy woman" to "breast cancer patient" in the time it took to read the letter, a transition experienced as sudden, disorienting, and, for many, disempowering.17

Qualitative syntheses describe the wait between notification and resolution as a period of uncertainty, intrusive thoughts, and searching for explanations.17,18 In Padgett et al. interviews with 45 African American women, lack of information and doubts about procedures accompanied fear of cancer.19 These accounts show how the process is experienced but do not allow estimation of how frequently such experiences occur among all women who receive a false positive.

Clarity, timeliness, and manner during communication emerge as relevant to restoring confidence after a benign result. Women described relief when they received understandable explanations and answers to their questions, while some retained doubts after ambiguous or incomplete messages.17,20 Qualitative research identifies needs and plausible mechanisms; it does not allow isolation of how much residual distress is attributable to communication versus other factors.

Clinical nurse specialists were identified as a valued source of support.17 Long et al. interviewed 12 professionals from a British unit, who perceived these nurses as particularly well prepared to support anxiety. Radiographers, by contrast, reported gaps in emotional training. Participants described drip-fed information, the use of scripts, and organizational limitations on individualized care.21 These are professional perceptions of a care practice, not an experimental demonstration of anxiety reduction.

Clinician-patient communication and organizational factors

The mixed-methods review by Williamson et al. included seven studies on communication of cancer-screening results to women. Verbal methods, by phone or in person, tended to improve understanding and were often preferred because they allowed questions. However, evidence on anxiety was scarce and contradictory, and did not allow an optimal channel to be established or telephone to be adequately distinguished from in-person consultation.22 A woman's preference, privacy, speed, and the opportunity to resolve doubts should be considered alongside the medium used.

In a prospective study of ten outpatient practices in Boston, Poon et al. evaluated 126 women with mammograms requiring short-term follow-up; 81 (64%) received appropriate follow-up. Documenting a plan in the medical record (adjusted OR 2.79; 95% CI 1.11-6.98) and the patient reporting awareness of the need for follow-up (adjusted OR 3.86; 1.50-9.96) were associated with better compliance.23 This supports the importance of a shared plan but does not demonstrate that a specific comprehension-verification intervention caused the improvement.

Jones et al. documented inadequate communication in 20.9% of 411 African American women and 10.9% of 734 White women; the association persisted after adjustment (OR 1.96; 95% CI 1.03-3.76).24 In another survey, Dolan et al. observed that satisfaction was related especially to the clarity of explanations.25 Comprehension, satisfaction, and anxiety are distinct outcomes: improvement in one cannot automatically be attributed to the others.

Kenny et al. interviewed 61 women from different ethnic groups and health systems. Two-way communication, plain language, and interpreter services emerged as facilitators of follow-up.26 Molina et al., in an exploratory sample of 82 women, found an association between talking with professionals and shorter time to follow-up, which was no longer significant after accounting for health coverage. Conversations with family and friends were also related to differences in distress by ethnicity.27 Possible confounding by healthcare access and the observational design preclude attributing an independent causal effect to these conversations.

Evidence on professional preparedness is limited but relevant. Murphy et al., in a survey of 300 primary care physicians in San Francisco, found that 73% (219 of 300) felt equipped to explain the core-biopsy process, but only 40% (120 of 300) considered themselves to have the expertise needed to answer questions about results: "PCPs reported having the expertise to discuss the results of breast biopsies with women less frequently than they reported feeling equipped to discuss the breast biopsy process."28 This lack of confidence was more pronounced when the patient came from a cultural background different from the physician's: difficulty with cross-cultural communication was the only factor independently associated with lower perceived expertise in the multivariable analysis (OR 0.26; 95% CI 0.11-0.63). From a complementary perspective, the ethnographic study by Gram et al. on Danish radiographers introduces the concept of "enskilment," an embodied, tacit, and social learning process through which these professionals, by working in both screening and diagnostic assessment, acquire the ability to recognize a recalled woman's anxiety and communicate with her more empathetically. A local practice born of this learning process, warning women at their first screening about the possibility of being recalled without this implying cancer, was perceived as reassuring without generating additional questions, making it, in the authors' words, "a time-efficient practice."29

Williamson et al. published a cluster-randomized crossover trial protocol comparing telephone and in-person communication of benign biopsy results.30 A protocol defines a research question but does not provide efficacy results. Bond et al., for their part, compared interviews with 21 women against British guidelines and proposed clarifying the reason for recall, the tests planned, the possibility of bringing a companion, and the availability of support.31 These proposals arise from needs expressed by women and should be distinguished from interventions with quantified effects.

The integration of artificial intelligence raises new questions about how to communicate discordant findings. Pesapane et al. conducted a randomized experimental survey with 600 women exposed to four hypothetical BI-RADS 1 scenarios. Disclosure of a discordance increased anxiety responses (58.0% versus 16.0% in the scenario without artificial intelligence); a contextual explanation reduced this proportion to 25.3%.32 The finding supports further investigation of contextualizing information but does not demonstrate a reduction in consultations, litigation, or persistent distress in clinical practice. The study measured responses and intentions regarding scenarios, not observed behaviors.

American Society of Clinical Oncology (ASCO) communication guidelines offer general principles: using clear language, exploring concerns, checking understanding, chunking complex information, and documenting relevant conversations.33,34 Applying them to screening is a reasonable extrapolation, since they were developed for oncology care. During work-up of an abnormal result, the explanation should distinguish that the finding does not equate to a cancer diagnosis from the still-premature statement that no cancer is present.

Interventions and scope of the evidence

Marcus et al. evaluated a culturally adapted brochure, added to the standard letter, in Black English-speaking women with an incomplete mammogram. Of 106 randomized women, 51 completed the survey. No significant difference was found in knowledge of the result or the plan; intervention-group respondents considered follow-up more common (OR 25.91; p=0.029) and additional mammography less frightening (OR 0.24; p=0.021).35 The finding is promising, but the low response rate limits its interpretation, and fear of a test is not equivalent to a clinical outcome of persistent anxiety.

Lee et al. studied seven community education sessions led by a radiologist, with 117 participants and pre- and post-questionnaires. Attendees reported better understanding and lower anxiety after the sessions, with no independent comparison group. The 75-100% anxiety reductions associated with immediate results or image review reflected participants' expectations about these services, not effects observed upon implementing them.36 The sample was also not restricted to women with false positives.

Obadina et al. randomized 130 women with an abnormal mammogram to a digital support module (Early CHESS) or a list of accredited websites. They found a favorable difference in anxiety at the time of biopsy, but not during the initial diagnostic work-up or in breast-cancer worry.37 The biopsy analysis was restricted to the subgroup that reached that procedure. Prior interaction with the clinical team may explain this, along with greater use of or motivation to use the resource; the design did not isolate the effect of interpersonal support or show that it was necessary for the digital intervention's efficacy.

Gutzeit et al. randomized 141 patients with BI-RADS 1 or 2 to receive or not receive the radiologist's business card. Recall of the radiologist's name and perceived ability to make contact improved, with no difference in overall satisfaction.38 The intervention facilitates continuity and accessibility but was not an evaluation of anxiety reduction after false positives.

Chiarelli et al. retrospectively compared two care pathways among 9,044 women with screen-detected cancer. Coordinated-assessment centers had a shorter median time to diagnosis (28 versus 39 days) and a higher adjusted probability of diagnosis within seven weeks (OR 1.91; 95% CI 1.73-2.10).39 Coordination may reduce waiting, but the study did not directly assess anxiety, nor did it include a false-positive cohort as the analytic population.

More direct evidence comes from the controlled trial by Barton et al. on immediate reading and anxiety-coping education. Among women with false positives, immediate reading was associated with a lower Impact of Event Scale score at three weeks (4.42 versus 5.53; p=0.026); the educational intervention showed no difference in psychological outcomes.40 This illustrates that reorganizing care and providing education can have different effects. Table 2 summarizes the scope and limitations of the interventions selected.

Table 2. Selected interventions and interpretive limitations

StudyDesign and populationOutcome assessedMain limitation
Marcus et al.35Pilot trial; incomplete mammogram. 106 randomized; 51 surveyed.Less fear of additional mammography; no significant difference in knowledge.Low response; perception-based outcomes; no evidence of durable effect.
Lee et al.36Community education; 117 participants; before/after, no independent comparison group.Better understanding and lower perceived anxiety after the session.General population; immediate, self-reported effects. The 75-100% figure was an expectation.
Obadina et al.37Randomized pilot; 130 women with an abnormal mammogram.Lower anxiety at biopsy; no initial difference or difference in cancer worry.Small biopsy subgroup; interpersonal mechanism not isolated.
Gutzeit et al.38Randomized; 141 BI-RADS 1-2 patients; contact card.Better recall of the radiologist and perceived ability to make contact.Did not study anxiety after false positives; indirect evidence.
Chiarelli et al.39Retrospective cohorts; 9,044 women with screen-detected cancer.Median diagnostic time of 28 versus 39 days with coordinated care.Time-based outcome; did not measure anxiety in false positives.
Barton et al.40Controlled trial; immediate reading and education; false-positive analysis.Lower IES at three weeks with immediate reading; education showed no detectable effect.Specific, short-term effect; does not demonstrate prevention of persistent distress.

IES: Impact of Event Scale. The table distinguishes psychological outcomes from comprehension, accessibility, and diagnostic-timeline outcomes. It does not constitute a formal certainty-of-evidence rating.

ASCO's integrative oncology and anxiety/depression management guidelines are directed at people with cancer or survivors.41,42 They may offer principles for assessment and referral where clinically relevant distress exists, but their therapeutic recommendations should not be presented as evidence specific to women with a false-positive mammogram.

Informed decision-making and preferences

Mathioudakis et al. synthesized 22 studies on values and preferences: women tended to value early detection and to accept some harms, although doubts persisted about their understanding of overdiagnosis.43 Pillay et al., in an update of 82 studies, documented variability in preferences and in the certainty of the estimates.44 These preferences should be interpreted in light of the information received, the population, and how benefits and harms are presented. Overdiagnosis involves detecting a cancer that would not have caused symptoms or death; it is distinct from a false positive, in which cancer is not confirmed.

Hersch et al. discussed, in 2011, the challenges of informing women about screening in a balanced way; that article is a discussion of the evidence, not a clinical trial.45 In a later analysis of a trial with 811 women, providing information about overdetection improved knowledge and decreased intentions to participate. The mediation analysis implicated cognitive and affective pathways, in particular knowledge, attitudes, and anticipated regret; breast-cancer worry was not a relevant mediator. Because mediators and intention were measured cross-sectionally, the causal sequence was not established.46 A lower intention to participate after receiving balanced information does not necessarily constitute a communication failure.

Discussion and Clinical Implications

The evidence reviewed supports three main conclusions. A false-positive result is associated with breast-cancer-specific distress whose intensity and course vary between women. Women and professionals consistently identify information and support needs during the diagnostic process, many of which concern how uncertainty is communicated. Some interventions show favorable results, but the evidence does not establish that improving communication alone prevents persistent psychosocial consequences or restores future attendance. Keeping these levels of evidence separate prevents observational associations or plausible proposals from being presented as demonstrated effects.

Interpretation of the findings

The contrast between specific and generic outcomes is the most consistent finding in this literature.1,3,4 Condition-specific instruments may be more sensitive to a reaction focused on breast cancer, or the false positive may generate a circumscribed concern rather than a generalized disturbance. Either way, the absence of differences on generic scales should not be read as absence of harm, nor should higher specific scores be equated with psychiatric morbidity. Average effects also conceal a wide range of responses: in the interviews by Bond et al., reactions ranged from nonchalance to extreme fear, and for some women uncertainty lingered until their next normal mammogram.20 Brett et al. identified factors associated with greater psychological impact, including younger age, lower educational level, dissatisfaction with information and communication, the waiting time between recall and assessment, pain during procedures, a previous false positive, and higher perceived risk.47 Several of these are modifiable aspects of care. At the population level, a disutility that is small for each woman, estimated at 0.03 to 0.04 with low certainty,44 becomes relevant because false positives are frequent;2 their frequency is therefore part of the psychological question and not only a technical performance indicator.

Across study designs, the period of uncertainty emerges as the moment of greatest vulnerability. Anxiety rises after notification and falls once the result is resolved,9 women describe waiting as the worst aspect of being recalled,17,20 and return to routine screening was lowest after short-interval follow-up rather than after biopsy.15 Bond et al. described a "crisis of visibility": seeing the image of a lesion makes the possibility of cancer concrete before any diagnosis exists.20 This interpretation has two implications. Shortening and coordinating the path to resolution addresses one source of distress directly, as suggested by the effect of immediate reading in the trial by Barton et al.40 and by the shorter diagnostic times of coordinated assessment.39 In addition, the aim of communication is not to eliminate uncertainty, which is inherent to diagnosis, but to make it understandable. Because unclear explanations of the final result were associated with lasting worry,17 communicating a benign result is part of care and not merely the administrative closure of the episode.

The vocabulary of screening also matters. Terms such as "positive," "abnormal," or "recall" may be heard as a diagnosis; the 2026 ASCO update cites "positive test result" as an example of jargon to avoid.34 Pillay et al. noted that information materials usually described false positives as findings suspicious of cancer, without mentioning that many results are incomplete or probably benign.44 Informing women at their first screening that they might be recalled without this implying cancer was perceived as reassuring in the Danish setting,29 although its effect on distress has not been formally evaluated.

Finally, the relationship between false positives and future attendance raises an ethical tension. Preventing women from abandoning screening after a negative experience is a legitimate goal, but higher attendance should not become the only measure of successful communication. The heterogeneity of associations across countries suggests that invitation practices, costs, and follow-up pathways may also influence return, in addition to the individual experience.3,5 Information about overdetection reduced the intention to participate in the trial analyzed by Hersch et al.;46 good communication may lead some women to continue screening and others to decline it, and both are legitimate outcomes when they result from an informed decision.45

Implications for practice and screening programs

In practice, communication can be organized by point of care. Before screening, explaining the possibility of a recall and offering balanced information helps women anticipate results that might otherwise feel unexpected.29,43,45 When notifying an abnormal finding, it is worth stating what is known, what remains to be clarified, what the next steps are, and who will answer questions. The phrase "further testing is needed, and this does not equate to a diagnosis of cancer" preserves uncertainty without offering premature reassurance. Confirming that the woman can explain the plan in her own words aligns with general communication guidelines, although its specific effect in this context requires evaluation.23,34

During the evaluation, priorities are an identifiable point of contact, coordinated scheduling, and explanations adapted to language and individual needs.26,31,38 Once cancer has been ruled out, the definitive result and the recommended follow-up should be communicated, residual doubts explored, and further evaluation offered if distress persists or affects daily life. Because communication gaps were more frequent among minority and language groups,24,26 and primary care physicians felt less prepared to discuss biopsy results than the procedure itself,28 training should reach radiographers, nurses, and primary care physicians, and not only breast specialists. These practices respond to needs described in the studies; they do not constitute a validated protocol as a set. Table 3 summarizes them by stage of care, together with the type of evidence that supports each one.

Table 3. Communication of a screening recall by stage of care

Stage of carePractices consistent with the evidenceSupporting evidence (type)
Before screeningInform women that they may be recalled without this implying cancer; provide balanced information on benefits and harms.Ethnographic study29; systematic review of preferences43; discussion paper and trial45,46
Notification of an abnormal resultState what is known, what remains to be clarified, the next steps, and who to contact; avoid jargon such as "positive"; check understanding.Qualitative syntheses17,20; prospective cohort23; guideline34
Diagnostic assessmentIdentifiable point of contact; coordinated scheduling and short waits; explanations adapted to language, with interpreter access.Qualitative studies26,31; randomized study38; retrospective cohort39; controlled trial40
Benign resultCommunicate the definitive result and the next screening clearly; explore residual doubts.Qualitative syntheses17,20
After resolutionOffer further evaluation if distress persists or affects daily life.Guidelines for people with cancer, extrapolated41,42
Program levelKeep recall rates within quality standards; monitor waiting times, comprehension, and condition-specific distress; train radiographers, nurses, and primary care physicians; define how discordant AI interpretations are communicated.Systematic review2; qualitative study21; cross-sectional survey28; experimental survey32

AI: artificial intelligence. The practices listed are consistent with the evidence reviewed but have not been validated as a set; the type of supporting evidence is indicated for each stage.

At the institutional level, improving care requires defining responsibility for communicating results and closing the loop on follow-up, ensuring access to interpretation services, and providing a consistent point of reference, such as a clinical nurse specialist, where resources allow.21,26 The most direct way to reduce this harm, however, is to avoid unnecessary recalls by keeping recall rates within quality standards.2 Programs could monitor recall rates and waiting times together with comprehension, condition-specific distress, and subsequent decisions; satisfaction or shorter waits do not substitute for measuring anxiety. As artificial intelligence is incorporated into screening, programs should also define in advance how discordant interpretations will be resolved and communicated, since disclosure of a discordance increased anxious responses in an experimental study.32

Limitations and research priorities

Interpretation is limited by heterogeneity in instruments, populations, and assessment time points; the predominance of observational studies; and limited experimental evidence. Several publications draw on the same Danish cohort, and reviews share primary studies, so the number of references does not equate to independent replications. Several key studies predate the widespread use of digital mammography and tomosynthesis, and current recall pathways may differ. Narrative selection and a PubMed-centered search may omit relevant literature. None of the included studies was conducted in Latin America, and evidence from high-income countries does not directly represent the region's health systems.

In Uruguay and other settings in the region, it would be worthwhile to assess communication pathways, diagnostic timelines, and support needs before transferring organizational models. Research priorities include trials using validated condition-specific measures, follow-up after benign resolution, and evaluation of differential effects by language, educational level, access, and prior experience. Studies are also needed that distinguish whether interventions improve comprehension, well-being, and informed decision-making, and under what conditions such changes relate to continuity of follow-up.

Conclusion

A false-positive mammogram can produce specific distress that persists after cancer has been ruled out, although its magnitude and duration vary and should not be confused with diagnosed psychiatric disorders. Clear, accessible communication that is sensitive to uncertainty is a relevant component of care and a reasonable target for improvement. The intervention evidence is heterogeneous and still insufficient to attribute to communication a uniform effect on long-term anxiety or future attendance. Programs should evaluate their improvements using psychological, comprehension, and follow-up outcomes, while preserving each woman's informed decision-making.

Declarations

Conflicts of Interest
The authors declare no conflicts of interest.
Funding
The authors received no funding for this work.

References

  1. Bond M, Pavey T, Welch K, et al. Systematic review of the psychological consequences of false-positive screening mammograms. Health Technol Assess. 2013;17(13):1-170. doi:10.3310/hta17130
  2. Nelson HD, Pappas M, Cantor A, Griffin J, Daeges M, Humphrey L. Harms of breast cancer screening: systematic review to update the 2009 U.S. Preventive Services Task Force recommendation. Ann Intern Med. 2016;164(4):256-267. doi:10.7326/M15-0970
  3. Brewer NT, Salz T, Lillie SE. Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med. 2007;146(7):502-510. doi:10.7326/0003-4819-146-7-200704030-00006
  4. Salz T, Richman AR, Brewer NT. Meta-analyses of the effect of false-positive mammograms on generic and specific psychosocial outcomes. Psychooncology. 2010;19(10):1026-1034. doi:10.1002/pon.1676
  5. Salz T, DeFrank JT, Brewer NT. False positive mammograms in Europe: do they affect reattendance? Breast Cancer Res Treat. 2011;127(1):229-231. doi:10.1007/s10549-010-1245-9
  6. Brodersen J, Siersma VD. Long-term psychosocial consequences of false-positive screening mammography. Ann Fam Med. 2013;11(2):106-115. doi:10.1370/afm.1466
  7. Long HA, Hindmarch S, Martindale J-P, Brooks JM, Harvie M, French DP. Emotion constructs and outcome measures following false positive breast screening test results: a systematic review of reporting clarity and selection rationale. Psychooncology. 2024;33(4):e6334. doi:10.1002/pon.6334
  8. Bond M, Pavey T, Welch K, et al. Psychological consequences of false-positive screening mammograms in the UK. Evid Based Med. 2013;18(2):54-61. doi:10.1136/eb-2012-100608
  9. Heckman BD, Fisher EB, Monsees B, Merbaum M, Ristvedt S, Bishop C. Coping and anxiety in women recalled for additional diagnostic procedures following an abnormal screening mammogram. Health Psychol. 2004;23(1):42-48. doi:10.1037/0278-6133.23.1.42
  10. Espasa R, Murta-Nascimento C, Bayés R, et al. The psychological impact of a false-positive screening mammogram in Barcelona. J Cancer Educ. 2012;27(4):780-785. doi:10.1007/s13187-012-0349-9
  11. Metsälä E, Pajukari A, Aro AR. Breast cancer worry in further examination of mammography screening - a systematic review. Scand J Caring Sci. 2012;26(4):773-786. doi:10.1111/j.1471-6712.2011.00961.x
  12. Gharaibeh MM, Elobeid EA, Ahmmed SM, et al. False-positive mammogram has a negative impact on quality of life: a cross-sectional study among Jordanian women at King Abdullah University Hospital. Medicine (Baltimore). 2026;105(22):e48990. doi:10.1097/MD.0000000000048990
  13. Gram EG, Siersma V, Brodersen JB. Long-term psychosocial consequences of false-positive screening mammography: a cohort study with follow-up of 12-14 years in Denmark. BMJ Open. 2023;13(4):e072188. doi:10.1136/bmjopen-2023-072188
  14. Heleno B, Siersma VD, Brodersen J. Diagnostic invasiveness and psychosocial consequences of false-positive mammography. Ann Fam Med. 2015;13(3):242-249. doi:10.1370/afm.1762
  15. Miglioretti DL, Abraham L, Sprague BL, et al. Association between false-positive results and return to screening mammography in the Breast Cancer Surveillance Consortium cohort. Ann Intern Med. 2024;177(10):1297-1307. doi:10.7326/M24-0123
  16. Mottram R, Knerr WL, Gallacher D, et al. Factors associated with attendance at screening for breast cancer: a systematic review and meta-analysis. BMJ Open. 2021;11(11):e046660. doi:10.1136/bmjopen-2020-046660
  17. Long H, Brooks JM, Harvie M, Maxwell A, French DP. How do women experience a false-positive test result from breast screening? A systematic review and thematic synthesis of qualitative studies. Br J Cancer. 2019;121(4):351-358. doi:10.1038/s41416-019-0524-4
  18. Health Quality Ontario. Women's experiences of inaccurate breast cancer screening results: a systematic review and qualitative meta-synthesis. Ont Health Technol Assess Ser. 2016;16(16):1-22.
  19. Padgett DK, Yedidia MJ, Kerner J, Mandelblatt J. The emotional consequences of false positive mammography: African-American women's reactions in their own words. Women Health. 2001;33(3-4):1-15. doi:10.1300/J013v33n03_01
  20. Bond M, Garside R, Hyde C. A crisis of visibility: the psychological consequences of false-positive screening mammograms, an interview study. Br J Health Psychol. 2015;20(4):792-806. doi:10.1111/bjhp.12142
  21. Long HA, Brooks JM, Maxwell AJ, Peters S, Harvie M, French DP. Healthcare professionals' experiences of caring for women with false-positive screening test results in the National Health Service Breast Screening Programme. Health Expect. 2024;27:e14023. doi:10.1111/hex.14023
  22. Williamson S, Patterson J, Crosby R, et al. Communication of cancer screening results by letter, telephone or in person: a mixed methods systematic review of the effect on attendee anxiety, understanding and preferences. Prev Med Rep. 2019;13:189-195. doi:10.1016/j.pmedr.2018.12.016
  23. Poon EG, Haas JS, Puopolo AL, et al. Communication factors in the follow-up of abnormal mammograms. J Gen Intern Med. 2004;19(4):316-323. doi:10.1111/j.1525-1497.2004.30357.x
  24. Jones BA, Reams K, Calvocoressi L, Dailey A, Kasl SV, Liston NM. Adequacy of communicating results from screening mammograms to African American and White women. Am J Public Health. 2007;97(3):531-538. doi:10.2105/AJPH.2005.076349
  25. Dolan NC, Feinglass J, Priyanath A, Haviley C, Sorensen AV, Venta LA. Measuring satisfaction with mammography results reporting. J Gen Intern Med. 2001;16(3):157-162. doi:10.1111/j.1525-1497.2001.00509.x
  26. Kenny JD, Karliner LS, Kerlikowske K, Kaplan CP, Fernandez-Lamothe A, Burke NJ. Organization communication factors and abnormal mammogram follow-up: a qualitative study among ethnically diverse women across three healthcare systems. J Gen Intern Med. 2020;35(10):3000-3006. doi:10.1007/s11606-020-05972-2
  27. Molina Y, Beresford SAA, Hayes-Constant T, Thompson B. Conversations about abnormal mammograms on distress and timely follow-up across ethnicity. J Cancer Educ. 2017;32(2):320-327. doi:10.1007/s13187-015-0918-9
  28. Murphy KA, Livaudais-Toman J, Kaplan CP, Kerlikowske K, Burke NJ, Karliner LS. Assessing preparedness of primary care physicians to discuss the breast biopsy process and results after abnormal mammograms: a cross-sectional survey. J Womens Health. 2026;35(2):144-151. doi:10.1177/15409996251396843
  29. Gram EG, Jønsson ABR, Larsen LB, Adlouni M, Mussmann B. Communicating the risk of recall in mammography screening: enskilment in breast radiography. Radiography. 2025;31(1):139-145. doi:10.1016/j.radi.2024.10.025
  30. Williamson SZ, Johnson R, Sandhu HK, et al. Communicating benign biopsy results by telephone in the NHS Breast Screening Programme: a protocol for a cluster randomised crossover trial. BMJ Open. 2019;9(9):e028679. doi:10.1136/bmjopen-2018-028679
  31. Bond M, Garside R, Hyde C. Improving screening recall services for women with false-positive mammograms: a comparison of qualitative evidence with UK guidelines. BMJ Open. 2015;5(2):e005855. doi:10.1136/bmjopen-2014-005855
  32. Pesapane F, Depretto C, Rotili A, et al. Should AI results be disclosed in mammography reports? A randomised survey study of patient responses to concordant and discordant interpretations. Eur Radiol. 2026;36:5645-5655. doi:10.1007/s00330-026-12405-x
  33. Gilligan T, Bohlke K, Baile WF. Patient-clinician communication: American Society of Clinical Oncology consensus guideline summary. J Oncol Pract. 2018;14(1):42-46. doi:10.1200/JOP.2017.027144
  34. Gilligan T, Bohlke K, Alpert AB, et al. Patient-clinician communication: ASCO guideline update. J Clin Oncol. 2026;44(11):1040-1057. doi:10.1200/JCO-26-00118
  35. Marcus EN, Sanders LM, Jones BA, Koru-Sengul T. A brochure to improve understanding of incomplete mammogram results among Black women at a public hospital in Miami, Florida. South Med J. 2019;112(1):27-32. doi:10.14423/SMJ.0000000000000919
  36. Lee J, Hardesty LA, Kunzler NM, Rosenkrantz AB. Direct interactive public education by breast radiologists about screening mammography: impact on anxiety and empowerment. J Am Coll Radiol. 2016;13(11S):R89-R97. doi:10.1016/j.jacr.2016.09.033
  37. Obadina ET, Dubenske LL, McDowell HE, et al. Online support: impact on anxiety in women who experience an abnormal screening mammogram. Breast. 2014;23(6):743-748. doi:10.1016/j.breast.2014.08.002
  38. Gutzeit A, Fischmann A, Forstner R, et al. "I was seen by a radiologist, but unfortunately I can't remember the name and I still have questions. What should I do?" Radiologists should give thoughts to improve service professionalism and patient esteem. Cancer Imaging. 2020;20:18. doi:10.1186/s40644-020-0292-7
  39. Chiarelli AM, Muradali D, Blackmore KM, et al. Evaluating wait times from screening to breast cancer diagnosis among women undergoing organised assessment vs usual care. Br J Cancer. 2017;116(10):1254-1263. doi:10.1038/bjc.2017.87
  40. Barton MB, Morley DS, Moore S, et al. Decreasing women's anxieties after abnormal mammograms: a controlled trial. J Natl Cancer Inst. 2004;96(7):529-538. doi:10.1093/jnci/djh083
  41. Carlson LE, Ismaila N, Addington EL, et al. Integrative oncology care of symptoms of anxiety and depression in adults with cancer: Society for Integrative Oncology-ASCO guideline. J Clin Oncol. 2023;41(28):4562-4591. doi:10.1200/JCO.23.00857
  42. Pirl WF, Nekhlyudov L, Rowland JH, Lacchetti C, Andersen BL. Management of anxiety and depression in adult survivors of cancer: ASCO guideline update Q&A. JCO Oncol Pract. 2023;19(10):714-717. doi:10.1200/OP.23.00324
  43. Mathioudakis AG, Salakari M, Pylkkanen L, et al. Systematic review on women's values and preferences concerning breast cancer screening and diagnostic services. Psychooncology. 2019;28(5):939-947. doi:10.1002/pon.5041
  44. Pillay J, Guitard S, Rahman S, et al. Patient preferences for breast cancer screening: a systematic review update to inform recommendations by the Canadian Task Force on Preventive Health Care. Syst Rev. 2024;13:140. doi:10.1186/s13643-024-02539-8
  45. Hersch J, Jansen J, Irwig L, et al. How do we achieve informed choice for women considering breast screening? Prev Med. 2011;53(3):144-146. doi:10.1016/j.ypmed.2011.06.013
  46. Hersch J, McGeechan K, Barratt A, et al. How information about overdetection changes breast cancer screening decisions: a mediation analysis within a randomised controlled trial. BMJ Open. 2017;7(10):e016246. doi:10.1136/bmjopen-2017-016246
  47. Brett J, Bankhead C, Henderson B, Watson E, Austoker J. The psychological impact of mammographic screening: a systematic review. Psychooncology. 2005;14(11):917-938. doi:10.1002/pon.904

Article information

Authors

  • Natalia CamejoAcademic Unit of Medical Oncology, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, UruguayCorresponding author · [email protected]
  • Cecilia CastilloAcademic Unit of Medical Oncology, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
  • Dahiana AmarilloAcademic Unit of Medical Oncology, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
  • María GuerrinaAcademic Unit of Medical Oncology, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
  • Virginia SuayaAcademic Unit of Medical Oncology, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
  • Gabriel KrygierAcademic Unit of Medical Oncology, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay

How to cite

Camejo, N., Castillo, C., et al., 2026. Psychological impact of false-positive results in breast cancer screening: the role of clinician-patient communication. Medical Research Archives, [online] 14(10). https://doi.org/10.18103/mra.2026.0721

Record

Journal
Medical Research Archives
Section
Review Articles
Published
31 October 2026
ISSN
2375-1924
Downloads
136

Copyright and licence

Published by the European Society of Medicine under a Creative Commons Attribution 4.0 International licence (CC BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original authors and source are credited.